The potentially lower risk of SARS-CoV-2 infection in patients with allergic asthma compared with nonallergic asthma could theoretically be explained by differences in expression of the key SARS-CoV-2 cellular receptor, angiotensin-converting enzyme 2 (ACE2). The gene discussed is ACE2; the disease is allergic asthma.